Recombinant protein · Agonist of insulin receptor (INSR) · developed by Oramed
ORMD-0801 is recombinant human insulin in an oral capsule formulation. It is studied as a potential therapeutic option in patients with type 1 diabetes, type 2 diabetes, brittle type 1 diabetes, and nonalcoholic fatty liver disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06731075 | Phase 3 | Type 2 Diabetes Mellitus | Not yet recruiting | ORMP |
| NCT04754334 | Phase 3 | T2DM (Type 2 Diabetes Mellitus) | Terminated | ORMP |
| NCT04606576 | Phase 3 | Type 2 Diabetes Mellitus | Terminated | ORMP |
| NCT04618744 | Phase 2 | Diabetes Mellitus, Type 2 | Completed | ORMP |
| NCT04150107 | Phase 2 | Type 1 Diabetes | Completed | ORMP |
| NCT02653300 | Phase 2 | Non-Alcoholic Steatohepatitis (NASH) | Completed | ORMP |
| NCT03467932 | Phase 2 | T2DM (Type 2 Diabetes Mellitus) | Completed | ORMP |
| NCT02954601 | Phase 2 | Type 2 Diabetes Mellitus | Completed | ORMP |
| NCT02535715 | Phase 2 | Type 1 Diabetes | Completed | ORMP |
| NCT02094534 | Phase 2 | Diabetes Mellitus Type 1 | Completed | ORMP |
| NCT01889667 | Phase 2 | Diabetes Mellitus Type 2 | Completed | ORMP |
| NCT00867594 | Phase 2 | Brittle Type I Diabetes Mellitus | Completed | ORMP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Brittle Type I Diabetes MellitusDiabetes Mellitus Type 1Diabetes Mellitus Type 2NASH - Nonalcoholic SteatohepatitisT2DM (Type 2 Diabetes Mellitus)Type 1 DiabetesType 2 Diabetes Mellitus
Updated Oct 3, 2026. Something wrong or missing? Report it on the ORMP page.
See ORMP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ORMP catalysts and pipeline →